With its revenue continuing to plummet—from $85 million in the first quarter to $65 million in the second—Amarin is restructuring under new leadership following a takeover of its board by activist investor Sarissa Capital three months ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,